

Inclinx Announces New Patent For Expert System Platform

Wilmington, N.C. —March 10, 2008— Inclinx, Inc., an enrollment contract research organization (CRO) and provider of clinical trial recruitment solutions, announced today that it has received a patent for its Expert System Platform (ESP). ESP is a software system that guides interview questions during patient qualification for clinical trials of new drugs or medical devices.

Inclinx advertises to recruit patients into clinical trials. Respondents to Inclinx advertising answer questions on a Web site or when interacting via phone with Inclinx TeleMEDICINE™ Contact Center representatives. The questions posed to respondents determine if the respondents fit the inclusion and exclusion criteria from the trial sponsor, usually a pharmaceutical company.

ESP dynamically organizes questions for the interview, changing question order or removing questions depending on the answers. ESP is particularly helpful for simultaneous trials. The system can automatically switch the prospective trial candidate to questions for a sponsor's second, third or fourth trial if he or she does not qualify for the first one.

ESP inventor and Inclinx Chief Operating Officer Chris Sleat said: "The way that the system is built turns the previous interviewing automation processes and logic on its head. With ESP, the data defines the screening logic, so users do not have to think about the structure or dependencies of the interview. ESP is vastly superior to a static interview script."

ESP includes the ability to leverage data from prior volunteers who have elected to be included in a database for consideration in future trials. EPS works well in combination with internal reporting systems.

ESP also supports novel medical questionnaires, and the platform has been used in homeland security applications. The design supports interviewing patients in terrorist incidents to see if they are victims of weapons of mass destruction. The ESP system initiates questions about multiple possible weapons exposure and then narrows the inquiry based on answers.

The patent number for the Expert System Platform is 7330842.

About Inclinux

Founded in 1999, Inclinux, Inc., is the industry's Enrollment CRO. Inclinux's IQM™ Intelligent Enrollment process uses technology to amplify traditional services and is proven to accelerate trials for pharmaceutical, biotechnology and medical-device organizations. In addition to its clinical research-related offerings, Inclinux provides strategic medical marketing communications and adherence services to the healthcare industry. For more information on Inclinux, visit www.inclinux.com

Press Contact:

Bill Gwinn
Inclinux, Inc.
(910) 332-2640
bgwinn@inclinux.com